Projects
The pharmaceutical projects listed in this phase are those that receive periodic global announcements.
Merck Invests more than US$130 million for Manufacturing Facility Expansion in France
Merck has invested more than US$130 million to improve its production capabilities for singleuse assemblies in Molsheim, France The expansion will boost production capabilities for singleuse assemblies from the Mobius portfolio
First North American Biomanufacturing Facility Opened in USA by WuXi Biologics
WuXi Biologics opened MFG18, its first GMP phase I drug substance clinical production facility, in Cranbury, New Jersey, USA With solely singleuse technology, the 154,448 square foot sites operational capacity for clinical manufacture will increase to 6,000 litres from its initial capacity of 4,000 litres
Horizon Therapeutics to Expand its Development, Manufacturing Facility in Ireland
Horizon Therapeutics plans to increase the size of its manufacturing and development facility in Waterford, Ireland The facility will increase the companys current 44,000 square foot drug product fillfinish biologics facility by about 320,000 square feet
Thermo Fisher Completes Expansion of its Cell Culture Media Site in USA
Thermo Fisher Scientific has finished the expansion of one of its manufacturing facilities for cell culture media, in Grand Island, New York, in the United States
Lonza Invests US$500 million to build a new Drug Facility in Switzerland
Lonza invests US$500 million for the construction of a new largescale commercial drug product fill and finish facility in Stein CH The new versatile facility will be built on the same campus as Lonzas current clinical medicinal product facility
TFF Pharmaceuticals plans R&D operations and expansion in the USA
TFF Pharmaceuticals intends to increase the size of its RD operations by bringing on a new research and development facility in Texas, USA The new facility, which is more than 3,500 square feet in size, will greatly boost TFFs total lab space and manufacturing
WuXi Biologics Invests US$1.4 billion in Singapore for a New CRDMO Center
WuXi Biologics will invest US$14 billion over ten years in a new CRDMO facility in Singapore The company will increase its capacity and capabilities for largescale drug substance and drug product DSDP manufacture as part of the plan
Deka Biosciences Plans to Expand its Germantown Facility in the USA
Deka Biosciences plans to expand its 14,000 square foot office and lab space at its Germantown facility in the United States To advance the development of their innovative cytokine therapeutics, the new facility will house a cuttingedge research and development, process development, and manufacturing facility
Catalent Invests $350 million in Drug Manufacturing Facility in Indiana
Catalent is investing US$350 million in Bloomington, Indiana to expand its biologics drug substance and therapeutic product manufacturing capabilities The project will support the industrys extensive biologics pipeline in a variety of ways Additionally, bioreactors, syringe filling lines, and lyophilization capacity
Seagen Plans Expansion of Cancer Biomanufacturing Facility in Washington
Seagen intends to expand its manufacturing facilities to gain more control and flexibility over the production of its cancer medications The 270,000squarefoot complex will be constructed north of the companys North American headquarters in Bothell, Washington
